Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Toxicological Effects
  • Genes that may be involved
  • Substrate of
  • Inhibits
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Oxsoralen, Uvadex; Belgium: Mopsoralen; Czech Republic: Oxsoralen; France: Meladinine; Germany: Meladinine, Uvadex; Greece: Melaoline, Uvadex; Hungary: Oxsoralen, Uvadex; Netherlands: Geroxalen, Uvadex; Poland: Geralen, Oxsoralen, Uvadex; Portugal: Uvadex; Slovakia: Oxsoralen; Spain: Oxsoralen.

North America

Canada: Oxsoralen, Ultramop; USA: Mop, Oxsoralen, Uvadex.

Latin America

Argentina: Oxsoralen; Brazil: Oxsoralen; Mexico: Dermox, Meladinina, Oxsoralen.


Japan: Oxsoralen.

Drug combinations


Methoxsalen: C~12~H~8~O~4~. Mw: 216.19. (1) 7H-Furo[3,2-g][1]benzopyran-7-one, 9-methoxy-; (2) 9-Methoxy-7H-furo[3,2-g][1]benzopyran-7-one. CAS-298-81-7.

Pharmacologic Category

Pigmenting Agents; Psoralen. (ATC-Code: D05AD02).

Mechanism of action

Bonds covalently to pyrimidine bases in DNA, inhibits synthesis of DNA, and suppresses cell division.

Therapeutic use

Symptomatic control of severe, recalcitrant disabling psoriasis (oral use). Repigmentation of idiopathic vitiligo (oral use). Palliative treatment of skin manifestations of cutaneous T-cell lymphoma (oral or extracorporeal use). Repigmentation of idiopathic vitiligo (topical use).

Pregnancy and lactiation implications

Fetal toxicity observed in animal studies. Use during pregnancy or lactation not recommended.

Unlabeled use


Hypersensitivity to methoxsalen (psoralens) or any component of the formulation. Diseases associated with photosensitivity (e.g. albinism, lupus erythematosus, porphyria (cutanea tarda, erythropoietic and variegate), xeroderma pigmentosum). Invasive squamous cell cancer. Aphakia. Melanoma or history of melanoma. Children <12 years of age.

Warnings and precautions

Serious burns might occur from ultraviolet radiation or sunlight if recommended dose and/or exposure schedule is not maintained. Eyes should be shielded from direct and indirect sunlight for 24 hours to prevent possible formation of cataracts. Therapy may lead to increased risk of skin cancer (basal cell, melanoma and squamous cell). Use with caution in multiple basal cell carcinomas or history of basal cell carcinoma, in cardiovascular disease (may not be able to tolerate the heat stress or prolonged standing related to UVA treatment conditions), and in hepatic impairment (hepatic metabolism). If used for treating psoriasis, should be administered only in conjunction with scheduled controlled doses of long-wave ultraviolet radiation. If used for treating vitiligo, should be used in conjunction with controlled doses of long-wave ultraviolet radiation or sunlight. Use caution with other (systemic or topical) photosensitizing drugs (e.g. thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides, anthralin, coal tar preparations). Use with caution in the elderly.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart